Each ml. of Oxsoralen Lotion contains 10 mg. methoxsalen in an inert vehicle containing alcohol (71% v/v), propylene glycol, acetone, and purified water. Methoxsalen is a naturally occurring substance found in the seeds of the Ammi majus (Umbelliferae) plant and in the roots of Heracleum Candicans. It belongs to a group of compounds known as psoralens or furocou-marins.
OXSORALEN (Methoxsalen TOPICAL) is indicated for the following:
As a topical repigmenting agent in vitiligo in conjunction with controlled doses of ultraviolet A (320-400 nm) or sunlight.
Media Articles Related to Oxsoralen (Methoxsalen Topical)
Drug for Rheumatoid Arthritis May Also Help Ease Vitiligo
Source: MedicineNet Vitiligo Specialty [2015.06.25]
Title: Drug for Rheumatoid Arthritis May Also Help Ease Vitiligo
Category: Health News
Created: 6/24/2015 12:00:00 AM
Last Editorial Review: 6/25/2015 12:00:00 AM
Source: MedicineNet Achalasia Specialty [2014.11.01]
Category: Diseases and Conditions
Created: 7/11/1999 12:00:00 AM
Last Editorial Review: 11/1/2014 12:00:00 AM
Published Studies Related to Oxsoralen (Methoxsalen Topical)
Randomized, double-blind comparison of 1 mg/L versus 5 mg/L methoxsalen bath-PUVA therapy for chronic plaque-type psoriasis. [2006.10]
BACKGROUND: Bath-psoralen plus ultraviolet A (PUVA) radiation therapy is increasingly replacing oral PUVA because of its superior short- and long-term safety profile. Several investigations in recent years have led to a refinement of the bath-PUVA protocol; however, the optimal therapeutic concentration of methoxsalen in the bath water has as yet not been delineated. OBJECTIVES: The therapeutic efficacy and tolerability of bath-PUVA by using two different dilutions of methoxsalen (1 mg/L vs 5 mg/L or 0.0001% vs 0.0005%) were compared in 46 patients with chronic plaque-type psoriasis in a prospective, randomized, double-blind study... CONCLUSIONS: Our data indicate that in bath-PUVA treatment the use of a high (5 mg/L) methoxsalen concentration is substantially more effective in clearing chronic plaque-type psoriasis than a low (1 mg/L) concentration.
Drug-drug interaction after single oral doses of the furanocoumarin methoxsalen and cyclosporine. [2006.07]
Furanocoumarins increase the bioavailability of drugs that are CYP3A4 substrates. A possible interaction of methoxsalen with cyclosporine was evaluated in 12 healthy volunteers following oral administration of 40 mg methoxsalen, 200 mg cyclosporine, or a combination of both in a randomized crossover study...
Clinical Trials Related to Oxsoralen (Methoxsalen Topical)
Safety and Efficacy of Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Crohn's Disease [Completed]
his study will explore the safety and activity of ECP treatment with UVADEX in inducing a
clinical response (i. e., a CDAI decrease greater than or equal to 100 from baseline and/or a
CDAI < 150) over a 12-week period in moderately active Crohn's disease (CDAI greater than or
equal to 220 to < 450) patients who are refractory or intolerant to immunosuppressants
and/or anti-TNF agents. This study will also assess response to continued treatment during
a 12-week Extension Period in patients who have a clinical response at Week 12 of the
Treatment Period and elect to participate in the Extension Period.
A Safety and Efficacy Study of Uvadex and Extracorporeal Photopheresis (ECP) in Chronic Graft Versus Host Disease [Active, not recruiting]
The purpose of this study is to evaluate the safety and effectiveness of extracorporeal
photopheresis therapy when added to standard drug therapies administered to patients with
moderate to severe chronic graft-versus-host disease.
Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Acute Graft Versus-Host Disease [Terminated]
The purpose of this study is to compare the safety and efficacy of ECP treatment combined
with high dose corticosteroids versus high dose corticosteroids alone, in the treatment of
patients with newly diagnosed acute GvHD (Grades II to III) that developed within 100 days
following an allo HPCT.
UVADEX® and ECP for the Treatment of Pediatric Patients With Steroid Refractory Acute Graft Versus Host Disease [Not yet recruiting]
This is a single-arm, open-label, multicenter study of the efficacy of UVADEX® (methoxsalen)
Sterile Solution in conjunction with THERAKOS® CELLEX® Photopheresis Systems in pediatric
patients with steroid-refractory aGvHD. The study is composed of Screening, Treatment, and
PUVA Maintenance Therapy in Mycosis Fungoides [Recruiting]
The purpose of the study is to determine whether psoralen plus UVA (PUVA) photochemotherapy
maintenance treatment prolongs disease-free survival of cutaneous T cell lymphoma (mycosis